Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLAM for Relapsed or Refractory AML
NCT02686593Phase 2Completed
- Sponsor
- The University of Hong Kong
- Start
- Feb 2016
- Primary completion
- Mar 2018
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of clofarabine, cytarabine and mitoxantrone in acute myeloid leukemia (AML), sponsored by The University of Hong Kong. Primary endpoint: Response rate at 28 days. Started Feb 2016; status: completed.
02
Drugs
clofarabinecytarabinemitoxantrone
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02686593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02686593.